Genentech
In January 1976, a twenty-eight-year-old venture capitalist named Robert Swanson walked into the laboratory of biochemist Herbert Boyer at the University of California. The meeting began with a cold call that resulted in a few beers and an agreement to start a pharmaceutical company. They invested five hundred dollars each to capitalize Genentech, seeking practical uses for engineered proteins. This small beginning launched what would become the world's first biotechnology corporation. Boyer had previously demonstrated how restriction enzymes could cut DNA fragments from one source. He showed that these pieces could be ligated into a plasmid vector. While his colleague Stanley Norman Cohen returned to academia, Swanson took the leap to build a business around this science.
Genentech achieved its first major scientific milestone by producing human somatostatin in 1977. Arthur Riggs and Keiichi Itakura worked alongside Boyer to express a human gene within bacteria. David Goeddel and Dennis Kleid joined the team to create synthetic human insulin in 1978. The U.S. Food and Drug Administration approved synthetic insulin in 1982 through a partnership with Eli Lilly and Company. This product became known as Humulin and was the first genetically engineered human therapeutic ever approved. Protropin followed as Genentech's first marketed drug to treat dwarfism. Sales of Protropin reached two billion dollars and helped establish the company as an industry leader. The FDA also approved Activase in 1987 to dissolve blood clots in patients suffering acute myocardial infarction.
F. Hoffmann-La Roche AG acquired a majority stake in Genentech in 1990. The Swiss pharmaceutical giant eventually bought all remaining shares for approximately forty-six point eight billion dollars in March 2009. Before this full acquisition, Genentech made strategic purchases to expand its portfolio. Tanox was acquired in 2006 for its development of Xolair. The deal allowed Genentech to retain more revenue from the asthma treatment. In July 2014, the company paid seven hundred twenty-five million dollars upfront to acquire Seragon Pharmaceuticals. Additional payments totaling one billion dollars depended on successful development of products within Seragon's pipeline. These moves transformed Genentech from a startup into a global biopharmaceutical powerhouse under Roche ownership.
Genentech maintained internal research while forming alliances with universities and other firms. A partnership with NewLink Genetics began in October 2014 with a one hundred fifty million dollar payment. This collaboration focused on checkpoint inhibitors for cancer treatment. The Data Incubator partnered with Genentech in June 2015 to train data scientists. A sixty million dollar deal signed in January 2015 gave access to genomic data held by 23andMe. Carmot Therapeutics joined forces with Genentech in August 2016 to discover new drug candidates. BioLineRx collaborated on a checkpoint inhibitor intended to pair with atezolizumab in September 2016. Epizyme conducted clinical trials exploring whether tazemetostat would work synergistically with Genentech's own therapies.
Corporate headquarters remain located in South San Francisco, California. Manufacturing facilities operate in Vacaville, Oceanside, and Hillsboro, Oregon. Lonza acquired the Vacaville site from Roche for twelve billion dollars in March 2024. Genentech sold its Porriño, Spain facility to Lonza in December 2006. Construction of an E. coli manufacturing facility began in Singapore in June 2007. This Singapore plant produces Lucentis bulk drug substance for worldwide distribution. Plans announced in 2023 included closing the South San Francisco manufacturing facility while expanding capabilities in Oceanside. These geographic shifts reflect changing production needs and strategic real estate decisions over decades.
A nine-year-old patent dispute concluded when Genentech agreed to pay two hundred million dollars to UCSF in November 1999. The university had sued for four hundred million dollars alleging theft of technology developed there. A jury ruled that the university's patent was valid in July 1999 but could not decide if Protropin relied on their research. The settlement distributed thirty million dollars to the University General Fund. Eighty-five million dollars went to three inventors and two collaborating scientists. Fifty million dollars funded a new teaching campus for UCSF. Thirty-five million dollars supported university-wide research efforts. This legal battle highlighted tensions between academic discovery and commercial application in early biotechnology.
Genentech serves as a donor to the Center for Health Care Strategies which lobbies the U.S. Government on Medicaid issues. The company maintains a Federal Political Action Committee to aggregate contributions from employees. In 2009, The New York Times reported that talking points appeared verbatim in official statements by Members of Congress. Representatives Joe Wilson and Blaine Luetkemeyer issued identical written statements drafted by Genentech lobbyists. These statements argued that outsourcing research to foreign countries like India harmed domestic job creation. The incident raised questions about the influence of pharmaceutical lobbying on national healthcare reform debates during that period.
Up Next
Continue Browsing
Common questions
When was Genentech founded and by whom?
Genentech was founded in January 1976 by venture capitalist Robert Swanson and biochemist Herbert Boyer. They invested five hundred dollars each to capitalize the company after a meeting at the University of California laboratory.
What was the first genetically engineered human therapeutic approved for Genentech?
The U.S. Food and Drug Administration approved synthetic insulin known as Humulin in 1982 through a partnership with Eli Lilly and Company. This product became the first genetically engineered human therapeutic ever approved.
Who acquired Genentech and when did the full purchase occur?
F. Hoffmann-La Roche AG acquired a majority stake in Genentech in 1990. The Swiss pharmaceutical giant eventually bought all remaining shares for approximately forty-six point eight billion dollars in March 2009.
Where is the corporate headquarters of Genentech located today?
Corporate headquarters remain located in South San Francisco, California. Manufacturing facilities operate in Vacaville, Oceanside, and Hillsboro, Oregon.
How much money did Genentech pay to resolve the patent dispute with UCSF?
Genentech agreed to pay two hundred million dollars to UCSF in November 1999 to conclude the nine-year-old patent dispute. A jury ruled that the university's patent was valid in July 1999 before the settlement distributed funds to inventors and research efforts.